Cargando…
Disruption of CCL2 in Mesenchymal Stem Cells as an Anti-Tumor Approach against Prostate Cancer
SIMPLE SUMMARY: Cancer cells and mesenchymal stem cells (MSCs) secrete C-C motif chemokine ligand 2 (CCL2), a small protein that attracts tumor-associated macrophages (TAMs), which promotes malignant progression, such as drug resistance and metastasis. In addition, MSCs can also be recruited by CCL2...
Autores principales: | Bui, Quoc Thang, Lee, Kuan-Der, Fan, Yu-Ching, Lewis, Branwen S., Deng, Lih-Wen, Tsai, Yuan-Chin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857005/ https://www.ncbi.nlm.nih.gov/pubmed/36672395 http://dx.doi.org/10.3390/cancers15020441 |
Ejemplares similares
-
Anti-cancer effect of danshen and dihydroisotanshinone I on prostate cancer: targeting the crosstalk between macrophages and cancer cells via inhibition of the STAT3/CCL2 signaling pathway
por: Wu, Ching-Yuan, et al.
Publicado: (2017) -
Roles of Interleukin-1 Receptor Antagonist in Prostate Cancer Progression
por: Fan, Yu-Ching, et al.
Publicado: (2020) -
CCL2 Disrupts the Adherens Junction: Implications for Neuroinflammation
por: Roberts, Toni K., et al.
Publicado: (2012) -
Tumor-derived interleukin-1 receptor antagonist exhibits immunosuppressive functions and promotes pancreatic cancer
por: Fan, Yu-Ching, et al.
Publicado: (2023) -
Enhancing the Therapeutic Potential of CCL2-Overexpressing Mesenchymal Stem Cells in Acute Stroke
por: Lee, Sanghun, et al.
Publicado: (2020)